BeiGene's first U.S. NDA tests global development strategy

BeiGene believes inclusion of data from trials run in China in the company’s first NDA to be reviewed by FDA could help build industry’s confidence in doing trials in China. BeiGene also hopes the strategy will help it accelerate global clinical development of its candidates.

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) CFO and Chief Strategy Officer Howard Liang told BioCentury that although the NDA for zanubrutinib to

Read the full 649 word article

User Sign In